All In Biotech

Drug Trial Radar · NCT07768943

GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma

A Prospective Multicenter Response-Adapted Treatment Study Based on Early Response Assessment After GELAD Induction Chemotherapy in Early-Stage Extranodal NK/T-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 620 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

620

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Jun 30, 2033

Study completion Jun 30, 2036

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective, multicenter study evaluates a response-adapted treatment strategy for previously untreated patients with early-stage extranodal NK/T-cell lymphoma of the upper aerodigestive tract. All participants receive two cycles of GELAD induction chemotherapy, followed by early response assessment using positron emission tomography/computed tomography (PET/CT) and plasma Epstein-Barr virus (EBV) DNA. Subsequent treatment is determined by the early response. Participants with complete metabolic response and negative EBV DNA enter PART A and are randomized 1:1 to standard-dose radiotherapy (50 Gy) or reduced-dose radiotherapy (40 Gy); both groups subsequently receive two additional cycles of GELAD. Participants with partial response and negative EBV DNA enter PART B and receive standard 50 Gy radiotherapy followed by two additional cycles of GELAD. Participants with stable disease, local or regional progressive disease that remains amenable to curative radiotherapy, or partial response with positive EBV DNA enter PART C and receive 50 Gy radiotherapy followed by response-adapted sintilimab consolidation. The primary objective of PART A is to determine whether reduced-dose radiotherapy is noninferior to standard-dose radiotherapy with respect to the 24-month progression-free survival rate. The primary objective of PART C is to evaluate the 24-month progression-free survival rate with response-adapted sintilimab consolidation in patients with a high-risk early response.

Conditions

  • Natural Killer/T-cell Lymphoma

Interventions

  • Gemcitabine (GEM)Drug

    Gemcitabine 1.0 g/m\^2 is administered intravenously on Day 1 of each 21-day GELAD cycle. All participants receive two induction cycles. Participants in PART A A0, PART A A1, and PART B receive two additional GELAD cycles after radiotherapy.

  • Etoposide InjectionDrug

    Etoposide 60 mg/m\^2 is administered intravenously on Days 1 through 3 of each 21-day GELAD cycle.

  • DexamethasoneDrug

    Dexamethasone 20 mg per day is administered intravenously on Days 1 through 4 of each 21-day GELAD cycle.

  • pegaspargaseDrug

    Pegaspargase 2000 U/m\^2, capped at 3750 U per dose, is administered intramuscularly on Day 1 of each 21-day GELAD cycle.

  • IMRT 50 GyRadiation

    Intensity-modulated radiotherapy is delivered at a total dose of 50 Gy in 25 fractions, 2.0 Gy per fraction, 5 fractions per week.

  • IMRT 40 GyRadiation

    Intensity-modulated radiotherapy is delivered at a total dose of 40 Gy in 20 fractions, 2.0 Gy per fraction, 5 fractions per week.

  • SintilimabDrug

    Sintilimab 200 mg is administered intravenously every 3 weeks after completion of radiotherapy in PART C. Treatment continues for at least 24 weeks. Sintilimab is discontinued when PET/CT complete metabolic response and plasma EBV DNA negativity have both been sustained for at least 24 weeks according to protocol-defined confirmation criteria. The maximum treatment duration is 24 months or 35 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 24-Month Progression-Free Survival Rate in PART ATime frame: From PART A randomization through 24 months
  2. 24-Month Progression-Free Survival Rate in PART CTime frame: From PART C module registration through 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.